Detalhe da pesquisa
1.
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9.
Eur J Clin Pharmacol
; 77(10): 1473-1484, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-33969434
2.
A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy.
Mov Disord
; 35(11): 1957-1965, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32882100
3.
Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study.
J Parkinsons Dis
; 11(3): 1079-1089, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34092654
4.
Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial.
Lancet Neurol
; 19(7): 591-600, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32562684
5.
CpG motifs are efficient adjuvants for DNA cancer vaccines.
J Invest Dermatol
; 123(2): 371-9, 2004 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-15245438
6.
Intraperitoneal administration of pMP6/liposome complexes inhibits the growth of co-localized colon-26 adenocarcinoma cells by inducing a tumor-specific immune response.
Anticancer Res
; 23(6C): 4843-51, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-14981934
7.
Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management.
PLoS One
; 9(12): e114469, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25474576
8.
Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod.
J Immunol
; 173(5): 3051-61, 2004 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15322165
9.
Granulocyte-macrophage colony-stimulating factor-based melanoma cell vaccines immunize syngeneic and allogeneic recipients via host dendritic cells.
J Immunol
; 171(10): 5180-7, 2003 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-14607918
10.
Induction of specific immune responses by polycation-based vaccines.
J Immunol
; 169(9): 5217-26, 2002 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12391240